Fintech PR
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
NetworkNewsWire Editorial Coverage
NEW YORK, Jan. 10, 2024 /PRNewswire/ — On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn’t just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1’s reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer’s and Parkinson’s to drug addiction, clinical trials are painting a stunning picture of GLP-1’s versatility. And it doesn’t stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.
- GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
- Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
- A pilot study evaluated a dose of the GLP-1 drug Rybelsus to one processed with DehydraTECH, showing Lexaria’s tech improves the safety and efficacy of the drug.
- Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial.
Diabetes and Obesity: A Growing Concern with a Glimmer of Hope
Imagine a silent storm raging inside countless bodies, a chronic battle against rising blood sugar. This is the reality for the 422 million people worldwide battling diabetes, a disease with tentacles that reach far beyond elevated glucose levels. Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.
The storm often gathers strength in the wake of another global health crisis: obesity. Data paints a disturbing picture — 41.9% of U.S. adults now obese, with the worldwide number ballooning to 1.9 billion in 2016 from about 650 million in 1975. This unholy alliance of diabetes and obesity affects a staggering 25% of the world and exacts a heavy toll, not just on health but also on the economy. A conservative estimate puts the global economic burden at more than $2 trillion.
Amid the storm clouds, a glimmer of hope emerges. Enter GLP-1 agonists as a new frontline defense. These drugs mimic a natural gut hormone, prompting the body to produce insulin, regulate blood sugar and even suppress appetite. They’re proving to be powerful weapons in the fight against both diabetes and obesity, offering a chance for a diabetes patient to reclaim control of their blood sugar.
The rising rate of diabetes and obesity diagnoses is creating unprecedented demand for innovative treatments. In 2022, the global diabetes drug market alone surged to $61.87 billion, a figure that pales in comparison to the projected tsunami of spending reaching ~$118 billion by 2032. Scientists are counting on GLP-1 drugs to fight obesity too, another market figured to also top $100 billion in the next decade.
GLP-1 agonists, already blockbusters for diabetes and obesity, are just getting going. That’s the potential Lexaria Bioscience Corp. (NASDAQ: LEXX) unlocks with its DehydraTECH platform. The DehydraTECH solution is designed to enhance drug delivery and efficacy, not only orally but even into the brain for centrally acting compounds. Consider bypassing injections and unlocking new treatment possibilities — that’s DehydraTECH’s revolutionary promise. With proven benefits for oral medications and potential for dissolvable oral applications, Lexaria positions itself at the forefront of maximizing the impact of these life-changing drugs.
Lexaria is initially focused on diabetes and obesity as the low-hanging fruit, but the company isn’t just tackling these indications with its DehydraTECH platform; it’s aiming for a whole menu of medical victories. This disruptive drug-delivery tech boasts faster, better absorption into both bloodstream and brain, making it applicable for conditions such as oral nicotine (where rapid delivery could be a major benefit). This isn’t simply hyperbole. Lexaria recently announced its first human GLP-1 study, with compelling results fueling excitement for a future where DehydraTECH supercharges the molecule’s effect. While diabetes and obesity are tremendous market opportunities, Lexaria is thinking bigger as a platter of medical hope.
DehydraTECH + Rybelsus(TM)
Lexaria Bioscience is aiming to plant its flag in the GLP-1 agonist space with its DehydraTECH platform. After early animal studies hinted at DehydraTECH’s blood-sugar-lowering abilities, the company’s first human test has impressed. DehydraTECH-powered Rybelsus(TM) (oral semaglutide), a blockbuster diabetes drug, lowered blood glucose levels much better than the original alone, possibly thanks to its superior delivery punch to deliver more of the GLP-1 drug into human bloodstream than did Rybelsus itself. It’s early in the game, but Lexaria commands attention to possibly improve the standard of care with a supercharged GLP-1 agonist.
Rybelsus is a top-selling drug in the diabetes market, posting sales of ~$1.63 billion in 2022 and recording $1.234 billion in sales during just the first half of 2023. Moreover, Ozempic, a weekly injectable semaglutide, registered sales of $6.174 billion in the first half of 2023. Recent studies by Lexaria show their platform boosts Rybelsus’ blood-sugar-bludgeoning power, which certainly opens discussions about the potential. The stakes are high to find the most efficacious oral medication considering that injections are a pain point for patients.
The research, conducted by a university researcher, completed a head-to-head comparison of Rybelsus alone versus DehydraTECH-formulated Rybelsus. Compared to a single dose of standard Rybelsus, DehydraTECH-powered Rybelsus showed sustained higher drug levels, quicker peak delivery, superior blood sugar control and even fewer side effects. The seven-participant study hints at a future where oral diabetes drugs could pack a much bigger punch, potentially giving injections a run for their money.
The data speaks volumes. At 24-hours post administration, blood-sugar levels in patients treated with Rybelsus were unchanged from baseline, while those in the DehydraTECH group experienced a 5.01% reduction, a significant improvement. Further, while the control group’s glucose soared 21.7% after a meal, DehydraTECH kept that number locked down to a mere 6.2%, showcasing its superior blood sugar control.
Besting a $1.8 Billion Technology
Armed with this data, Lexaria’s is moving forward with a purpose to validate and capitalize on its initial DehydraTECH results. The company is fast-tracking larger trials to confirm the improved efficacy and safety shown in the most recent research while its focus is firmly fixed on a commercial partnership.
Moving forward, Lexaria is planning to initiate multiple studies further proving the prowess of DehydraTECH. For starters, the company will conduct additional human pilot studies in the next several months to examine another GLP-1 drug as well as evaluate a swallow-free oral dissolvable. It will also launch a multiweek animal pharmacokinetic and efficacy trial to optimize DehydraTECH for weight loss and other performance metrics. Elsewhere, the company is in the planning stages for a long-term stability test program for the purpose of determining if DehydraTECH-formulated GLP-1 drugs can go unrefrigerated during storage, unlike today’s injectable GLP-1 drugs, a factor that will reduce cost and increase logistic simplicity.
Beginning in the April–June quarter, Lexaria has intentions to study DehydraTECH-GLP-1 in a multiweek chronic human trial. In this study, the company will gain insight in both diabetes-related control (in part via reduced blood sugar levels) as well as weight loss and side effects.
Predicting the DehydraTECH impact on the GLP-1 market is a difficult task at this point. The company is rapidly building a data set with the hopes of sealing a deal with an interested pharmaceutical giant. With whispers of efficacy multiplying and side effects diminishing, the potential to disrupt a multibillion-dollar market is, arguably, an achievable target.
To put this into perspective, understand that the last time a drug-delivery technology achieved such an improvement, Novo Nordisk agreed to pay $1.8 billion to acquire Emisphere’s SNAC technology, subsequently putting the technology into Rybelsus tablets. That bears repeating, considering the $1.8 billion technology currently embedded in Rybelsus tablets was just outperformed by DehydraTECH technology.
Proving More Differentiation
GLP-1 drugs are undoubtedly popular due to their efficacy and intriguing safety profile compared to other drugs for the same indications, but they are still far from perfect. Their side effects include diarrhea, vomiting, nausea and more. Plus, they are still somewhat new, so long-term research is ongoing to evaluate delayed effects that could be related to bone density and muscle loss. To wit, DehydraTECH improving pharmacokinetics to reduce side effects can be instrumental in gaining market share in the future.
In the pilot study, DehydraTECH impresses on this front. None of the participants treated with DehydraTECH-formulated Rybelsus experienced any moderate or severe nausea or diarrhea. Conversely, those receiving the Rybelsus control tablets dealt with moderate nausea and diarrhea.
Lexaria isn’t just about blockbuster potential, it’s about smart business. DehydraTECH delivers a double whammy: lower costs for pharma giants and higher demand from patients seeking better delivery and efficacy. And to lock this golden goose in, the company has built a fortress of patents – 38 already granted and counting across the globe.
Only the Beginning
With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of human afflictions, including neurological disorders (e.g., Alzheimer’s and Parkinson’s), cardiovascular conditions (e.g., heart disease, high blood pressure, atherosclerotic plaques, inflammation), cancer, autoimmune disease (e.g., Crohn’s), and many new possibilities. Additional companies and studies are investigating the efficacy of GLP-1 drugs on kidney disease, liver disease, bone health and even aging.
Amgen Inc. (NASDAQ: AMGN) is developing Maridebart cafraglutide (formerly AMG 133), or Mari for short. Mari is a gastric inhibitory polypeptide receptor (GIPR) antagonist and GLP-1 receptor agonist. It is being investigated in a phase 2 trial for the treatment of obesity with more than 640 patients, with and without diabetes, enrolled in the study.
Eli Lilly and Company (NYSE: LLY) recently announced that the U.S. Food and Drug Administration had approved its Zepbound(TM) (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems. Adults taking Zepbound in a clinical trial lost on average 48 pounds at the highest dose. Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
Roche (OTCQX: RHHBY) announced last month that it had entered into a definitive merger agreement to acquire Carmot Therapeutics Inc., a privately owned U.S. company based in California. Carmot’s R&D portfolio includes clinical-stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs. The announcement noted that existing clinical data for Carmot’s assets, especially the lead asset CT-388, suggests potential to achieve and maintain weight loss with differentiated efficacy.
WW International Inc. (NASDAQ: WW) last month launched a new behavior-change program designed to support the unique needs of individuals on GLP-1 medications. The WeightWatchers GLP-1 Program was developed by a team of obesity specialists, clinicians, behavior-change scientists, dietitians and fitness experts to solve a gap in the market as members navigate life on new weight-loss medications.
GLP-1 has transcended its initial promise — its story is now a thrilling saga of scientific exploration and medical triumph. The implications are vast, not only for the millions struggling with diverse ailments but for the future of medicine itself. This is just the beginning. The curtain has risen on a new era, where GLP-1, the once-humble diabetes drug, stands poised to rewrite the script for countless medical journeys.
For more information about Lexaria Bioscience Corp., please visit Lexaria Bioscience Corp.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire is powered by IBN
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, FNM, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
FNM & NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/glp-1-beyond-diabetes-a-blockbuster-horizon-beckons-302030757.html
OTTAWA, ON, Nov. 22, 2024 /PRNewswire/ — The Royal Canadian Mint (the “Mint”) announces its financial results for the third quarter of 2024 that provide insight into its activities, the markets influencing its businesses and its expectations for the next 12 months.
“As the markets continue to change, the Mint is proving its ability to seize on new opportunities thanks to its diversified structure and flexible business strategy” said Marie Lemay, President and CEO of the Royal Canadian Mint.
The financial results should be read in conjunction with the Mint’s annual report available at www.mint.ca . All monetary amounts are expressed in Canadian dollars, unless otherwise indicated.
Financial and Operational Highlights
- The financial results for the third quarter of 2024 were ahead of target and higher than 2023 levels. Higher gold market pricing and foreign circulation volumes combined with lower fixed costs were the main drivers for the quarter over quarter increase. These increases were partially offset by lower than expected bullion volumes from the continued soft demand in the global bullion market. The Mint expects to meet its financial goals for 2024, as set out in its 2024-2028 Corporate Plan, the Mint’s Leadership team continues to actively monitor its status.
- Consolidated revenue decreased to $252.7 million in 2024 (2023 – $360.6 million).
Revenue from the Precious Metals business decreased to $217.6 million in 2024
(2023 – $328.4 million):- Gold bullion volumes decreased 38% quarter over quarter to 106.1 thousand ounces (2023 – 170.1 thousand ounces) while silver bullion volumes decreased 20% to 2.7 million ounces (2023 – 3.4 million ounces).
- Gold and silver market prices increased quarter over quarter by 27% and 23%, respectively.
- Sales of numismatic products decreased 12% quarter over quarter mainly due to the high demand in 2023 for the Queen Elizabeth II’s Reign products.
- Revenue from the Circulation business increased to $35.1 million in 2024
(2023 – $32.2 million):- Revenue from the Foreign Circulation business increased 77% quarter over quarter, a reflection of higher volumes produced and shipped in 2024 as compared to 2023.
- Revenue from Canadian coin circulation products and services decreased 12% quarter over quarter as fewer coins were required to replenish inventories, combined with lower program fees in accordance with the memorandum of understanding with the Department of Finance.
- Overall, operating expenses decreased 27% quarter over quarter to $28.3 million (2023 – $36.0 million) mainly due to planned reductions in consulting and workforce expenses.
Consolidated results and financial performance
(in millions)
|
13 weeks ended |
39 weeks ended |
|||||||||||
|
Change |
Change |
|||||||||||
|
September |
September |
$ |
% |
September |
September 30, 2023 |
$ |
% |
|||||
|
Revenue |
$ |
252.7 |
$ 360.6 |
(107.9) |
(30) |
$ 861.2 |
$ 1,841.8 |
(980.6) |
(53) |
|||
|
Profit (loss) for the period |
$ |
5.7 |
$ (5.8) |
11.5 |
(198) |
$ 24.1 |
$ 15.0 |
9.1 |
61 |
|||
|
Profit (loss) before |
$ |
1.4 |
$ (8.7) |
10.1 |
(116) |
$ 12.3 |
$ 23.4 |
(11.1) |
(47) |
|||
|
Profit (loss) before |
0.6 % |
(2.4) % |
1.4 % |
1.3 % |
||||||||
|
(1) Profit (loss) before income tax and other items is a non-GAAP financial measure. A reconciliation from profit for the period to profit before income tax and other items is included on page 13 of the Mint’s 2024 Third Quarter Report. |
|
(2) Profit (loss) before income tax and other items margin is a non-GAAP financial measure and its calculation is based on profit before income tax and other items. |
|
As at |
||||||||||
|
September 28, 2024 |
December 31, 2023 |
$ Change |
% Change |
|||||||
|
Cash |
$ |
58.4 |
$ |
59.8 |
(1.4) |
(2) |
||||
|
Inventories |
$ |
71.5 |
$ |
68.8 |
2.7 |
4 |
||||
|
Capital assets |
$ |
174.2 |
$ |
173.0 |
1.2 |
1 |
||||
|
Total assets |
$ |
376.8 |
$ |
380.4 |
(3.6) |
(1) |
||||
|
Working capital |
$ |
99.2 |
$ |
97.8 |
1.4 |
1 |
||||
As part of its enterprise risk management program, the Mint continues to actively monitor its global supply chain and logistics networks in support of its continued operations. Despite its best efforts, the Mint expects changes in the macro-economic environment and other external events around the globe to continue to impact its performance in 2024. The Mint continues to mitigate potential risks as they arise through its enterprise risk management process.
To read more of the Mint’s Third Quarter Report for 2024, please visit www.mint.ca.
About the Royal Canadian Mint
The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours. As an established London and COMEX Good Delivery refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. As an organization that strives to take better care of the environment, to cultivate safe and inclusive workplaces and to make a positive impact on the communities where it operates, the Mint integrates environmental, social and governance practices in every aspect of its operations.
For more information on the Mint, its products and services, visit www.mint.ca. Follow the Mint on LinkedIn, Facebook and Instagram.
FORWARD LOOKING STATEMENTS AND NON-GAAP FINANCIAL MEASURES
This Earnings Release contains non-GAAP financial measures that are clearly denoted where presented. Non-GAAP financial measures are not standardized under International Financial Reporting Standards (IFRS) and might not be comparable to similar financial measures disclosed by other corporations reporting under IFRS.
This Earnings Release contains forward-looking statements that reflect management’s expectations regarding the Mint’s objectives, plans, strategies, future growth, results of operations, performance, and business prospects and opportunities. Forward-looking statements are typically identified by words or phrases such as “plans”, “anticipates”, “expects”, “believes”, “estimates”, “intends”, and other similar expressions. These forward-looking statements are not facts, but only estimates regarding expected growth, results of operations, performance, business prospects and opportunities (assumptions). While management considers these assumptions to be reasonable based on available information, they may prove to be incorrect. These estimates of future results are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from what the Mint expects. These risks, uncertainties and other factors include, but are not limited to, those risks and uncertainties set forth in the Risks to Performance section of the Management Discussion and Analysis in the Mint’s 2023 annual report, as well as in Note 9 – Financial Instruments and Financial Risk Management to the Mint’s Audited Consolidated Financial Statements for the year ended December 31, 2023. The forward-looking statements included in this Earnings Release are made only as of November 20, 2024 and the Mint does not undertake to publicly update these statements to reflect new information, future events or changes in circumstances or for any other reason after this date.
For more information, please contact: Alex Reeves, Senior Manager, Public Affairs, Tel: (613) 884-6370, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/royal-canadian-mint-reports-profits-and-performance-for-q3-2024-302314428.html
Fintech PR
OIVE and ViniPortugal celebrate closing of joint campaign that reached 100 million consumers
MADRID and PORTO, Portugal, Nov. 22, 2024 /PRNewswire/ — For three years, A Shared Passion showed European consumers the quality and unparalleled versatility of Iberian wines. The program reached over 100 million consumers with advertising in airports, train stations, press trips, digital content, and other actions with opinion leaders.
The wine interprofessionals of Spain (OIVE) and Portugal (ViniPortugal) celebrated the closing of their ambitious joint campaign A Shared Passion with flagship events in Madrid and Porto. The closing event in Spain took place in Madrid’s iconic Calle Alcalá, while in Portugal, the World of Wine (WOW) in Porto was the perfect setting to present the achievements of the international collaboration. Both ceremonies were very well received by the press and the wine sector, highlighting the impact of the promotional actions that reached more than 79.2 million travelers in key transport infrastructures.
The campaign included 22 study trips, taking 150 specialized journalists to explore the world of wine in both countries and generating publications that reached nearly 15 million European consumers.
On social media, the A Shared Passion profile on Instagram exceeded 15,000 followers, consolidating its presence in the digital sphere. In addition, exclusive activities such as workshops and VIP dinners contributed significantly to this initiative’s global impact.
The final events were honored by the presence of opinion leaders, such as Masters of Wine Pedro Ballesteros and Dirceu Vianna Júnior, who moderated round tables with the presidents of OIVE, Fernando Ezquerro, and ViniPortugal, Frederico Falcão. The conference concluded with masterclasses that highlighted Spain and Portugal’s extraordinary oenological diversity, reinforcing the relevance of the sector in the economic, social, and environmental sustainability of both countries.
With funding from the European Union, A Shared Passion highlighted not only the quality and authenticity of Iberian wines but also their strategic role in the sustainable development of numerous municipalities. This initiative underlines the passion with which Spanish and Portuguese wines are made, reflecting their rich traditions and commitment to the future.
For more information: www.asharedpassion.com
Video: https://mma.prnewswire.com/media/2565600/ViniPortugal_and_OIVE.mp4
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/oive-and-viniportugal-celebrate-closing-of-joint-campaign-that-reached-100-million-consumers-302314339.html
Fintech PR
Alkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
Alkira attributes its 7,194% revenue growth to consistent innovation, enabling enterprises to overcome mounting network complexity in the cloud and AI era
SAN JOSE, Calif., Nov. 22, 2024 /PRNewswire/ — Alkira® Inc., the leader in Network Infrastructure as a Service, today announced that it ranked as the 6th fastest-growing technology company in the Bay Area and the 25th fastest-growing company in North America on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. Now in its 30th year, the list recognized Alkira for achieving a growth rate of 7,194% during this period.
“Being recognized as one of North America’s fastest-growing companies by Deloitte is a tremendous honor. This achievement reflects Alkira’s unwavering commitment to equipping frontline networking teams with solutions that dramatically simplify enterprise networking amidst escalating complexity,” said Amir Khan, CEO at Alkira. “Today’s enterprises are racing to support cloud, AI and machine learning workloads, but their existing networks weren’t built for this dynamic environment. Alkira’s network infrastructure as-a-service platform enables organizations to connect any cloud, on-premise location, and remote user with a unified, secure, and highly scalable network fabric that reduces deployment times from months to minutes.”
“For 30 years we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” said Steve Fineberg, vice chair, U.S. technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”
“Innovation, transformation and disruption of the status quo are at the forefront for this year’s Technology Fast 500 list, and there’s no better way to celebrate 30 years of program history,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s Audit & Assurance practice. “This year’s winning companies have demonstrated a continuous commitment to growth and remarkable consistency in driving forward progress. We extend our congratulations to all of this year’s winners — it’s an incredible time for innovation.”
Overall, 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 186,373% over the three-year time frame, with an average growth rate of 2,097% and median growth rate of 458%.
Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Alkira
Alkira is the leader in Network Infrastructure on Demand. We unify any environments, sites, and users via an enterprise network built entirely in the cloud. The network is managed using the same controls, policies, and security systems network administrators know, is available as a service, and can instantly scale as needed. There is no new hardware to deploy, software to download, or architecture to learn. Alkira’s solution is trusted by Fortune 100 enterprises, leading system integrators, and global managed service providers. Learn more at alkira.com and follow us @alkiranet.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they build their future. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact at www.deloitte.com.
Media Contact:
Jelena Dopudj, Sr. Communications Manager, Alkira Marketing
[email protected]
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
Logo – https://mma.prnewswire.com/media/1743646/Alkira_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alkira-ranked-25th-fastest-growing-company-in-north-america-and-6th-in-the-bay-area-on-the-2024-deloitte-technology-fast-500-302313919.html
-
Fintech PR7 days agoSustainable Infrastructure Holding Company (“SISCO”) Q3FY24 revenue (excluding accounting construction revenue) increases by 23.8% to 341.8 million
-
Fintech2 days agoFintech Pulse: Industry Updates, Innovations, and Strategic Moves
-
Fintech PR7 days agoLaunch of Al Faisal Al Baladi Holding
-
Fintech1 day agoFintech Pulse: Daily Industry Brief – A Dive into Today’s Emerging Trends and Innovations
-
Fintech PR2 days agoROLLER Releases 2025 Attractions Industry Benchmark Report, Unveiling Key Trends and Revenue Strategies
-
Fintech PR2 days agoTAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
-
Fintech4 days agoFintech Pulse: Navigating Expansion, Innovation, and Sustainability
-
Fintech3 days agoFintech Pulse: Milestones, Partnerships, and Transformations in Fintech